136 related articles for article (PubMed ID: 34145572)
21. Successful unrelated bone marrow transplantation after arsenic trioxide treatment in a patient with relapsed acute promyelocytic leukemia.
Mikoshiba M; Ohashi K; Takei N; Okuyama Y; Maeda Y; Hiruma K; Akiyama H; Fukuhara O; Takeshita A; Sakamaki H
Int J Hematol; 2002 Jan; 75(1):104-6. PubMed ID: 11843281
[No Abstract] [Full Text] [Related]
22. Prolonged molecular remission after arsenic trioxide and all-trans retinoic acid for acute promyelocytic leukemia relapsed after allogeneic stem cell transplantation.
Grigg A; Kimber R; Szer J
Leukemia; 2003 Sep; 17(9):1916-7; author reply 1918. PubMed ID: 12970801
[No Abstract] [Full Text] [Related]
23. Two successful deliveries of healthy children by a young woman diagnosed and treated during induction and relapsed therapy for acute promyelocytic leukemia.
Dang CC; Guan YK; Lau NS; Chan SY
J Oncol Pharm Pract; 2020 Dec; 26(8):2034-2037. PubMed ID: 32279594
[TBL] [Abstract][Full Text] [Related]
24. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
25. Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy.
Cicconi L; Breccia M; Franceschini L; Latagliata R; Molica M; Divona M; Diverio D; Rizzo M; Ottone T; Iaccarino L; Alfonso V; Foa R; Voso MT; Lo-Coco F
Ann Hematol; 2018 Oct; 97(10):1797-1802. PubMed ID: 29951912
[TBL] [Abstract][Full Text] [Related]
26. Current treatment strategy of acute promyelocytic leukemia.
Mi J
Front Med; 2011 Dec; 5(4):341-7. PubMed ID: 22198746
[TBL] [Abstract][Full Text] [Related]
27. Successful treatment of acute promyelocytic leukemia in pregnancy with single-agent all-trans retinoic acid.
Nellessen CM; Janzen V; Mayer K; Giovannini G; Gembruch U; Brossart P; Merz WM
Arch Gynecol Obstet; 2018 Feb; 297(2):281-284. PubMed ID: 29110117
[TBL] [Abstract][Full Text] [Related]
28. Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia.
Breccia M; Foà R
Expert Rev Hematol; 2019 Feb; 12(2):81-87. PubMed ID: 30572725
[TBL] [Abstract][Full Text] [Related]
29. First report of successful management of acute promyelocytic leukemia in a pregnant female with All-Trans-Retinoic Acid and Arsenic Trioxide-based induction regimen.
Khosla H; Jain A; Tatawadiya S; Prasad P; Nagpal K; Chaudhry S; Sharma M; Gupta DK; Saluja S; Jain A
Blood Cells Mol Dis; 2020 Nov; 85():102476. PubMed ID: 32688220
[No Abstract] [Full Text] [Related]
30. Autologous hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission: outcomes before and after the introduction of arsenic trioxide.
Yanada M; Yano S; Kanamori H; Gotoh M; Emi N; Watakabe K; Kurokawa M; Nishikawa A; Mori T; Tomita N; Murata M; Hashimoto H; Henzan H; Kanda Y; Sawa M; Kohno A; Atsuta Y; Ichinohe T; Takami A
Leuk Lymphoma; 2017 May; 58(5):1061-1067. PubMed ID: 27701911
[TBL] [Abstract][Full Text] [Related]
31. Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia.
Au WY; Kumana CR; Kou M; Mak R; Chan GC; Lam CW; Kwong YL
Blood; 2003 Jul; 102(1):407-8. PubMed ID: 12814916
[No Abstract] [Full Text] [Related]
32. Don't just stand there, do something: strategies for the prevention of early death in acute promyelocytic leukemia: a commentary.
Tallman MS; Manji GA
Blood Cells Mol Dis; 2011 Feb; 46(2):173-4. PubMed ID: 21227722
[No Abstract] [Full Text] [Related]
33. Arsenic trioxide and all-trans retinoic acid treatment for childhood acute promyelocytic leukaemia.
Strocchio L; Gurnari C; Santoro N; Putti MC; Micalizzi C; Zecca M; Cuccurullo R; Girardi K; Diverio D; Testi AM; Lo-Coco F; Locatelli F
Br J Haematol; 2019 Apr; 185(2):360-363. PubMed ID: 30028005
[No Abstract] [Full Text] [Related]
34. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy.
Ghavamzadeh A; Alimoghaddam K; Ghaffari SH; Rostami S; Jahani M; Hosseini R; Mossavi A; Baybordi E; Khodabadeh A; Iravani M; Bahar B; Mortazavi Y; Totonchi M; Aghdami N
Ann Oncol; 2006 Jan; 17(1):131-4. PubMed ID: 16227315
[TBL] [Abstract][Full Text] [Related]
35. Outcome of acute promyelocytic leukemia (APL) in children and adolescents: an analysis in two consecutive trials of the European APL Group.
Bally C; Fadlallah J; Leverger G; Bertrand Y; Robert A; Baruchel A; Guerci A; Recher C; Raffoux E; Thomas X; Leblanc T; Idres N; Cassinat B; Vey N; Chomienne C; Dombret H; Sanz M; Fenaux P; Adès L
J Clin Oncol; 2012 May; 30(14):1641-6. PubMed ID: 22473162
[TBL] [Abstract][Full Text] [Related]
36. Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention.
Esteve J; Escoda L; Martín G; Rubio V; Díaz-Mediavilla J; González M; Rivas C; Alvarez C; González San Miguel JD; Brunet S; Tomás JF; Tormo M; Sayas MJ; Sánchez Godoy P; Colomer D; Bolufer P; Sanz MA;
Leukemia; 2007 Mar; 21(3):446-52. PubMed ID: 17205057
[TBL] [Abstract][Full Text] [Related]
37. Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial.
Cicconi L; Platzbecker U; Avvisati G; Paoloni F; Thiede C; Vignetti M; Fazi P; Ferrara F; Divona M; Albano F; Efficace F; Sborgia M; Di Bona E; Breccia M; Borlenghi E; Cairoli R; Rambaldi A; Melillo L; La Nasa G; Fiedler W; Brossart P; Hertenstein B; Salih HR; Annibali O; Wattad M; Lubbert M; Brandts CH; Hanel M; Rollig C; Schmitz N; Link H; Frairia C; Fozza C; Maria D'Arco A; Di Renzo N; Cortelezzi A; Fabbiano F; Dohner K; Ganser A; Dohner H; Amadori S; Mandelli F; Voso MT; Ehninger G; Schlenk RF; Lo-Coco F
Leukemia; 2020 Mar; 34(3):914-918. PubMed ID: 31611624
[No Abstract] [Full Text] [Related]
38. Treatment of paediatric APL: how does the therapeutic approach differ from adults?
Kutny MA; Gregory J; Feusner JH
Best Pract Res Clin Haematol; 2014 Mar; 27(1):69-78. PubMed ID: 24907019
[TBL] [Abstract][Full Text] [Related]
39. Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.
Adès L; Thomas X; Bresler AG; Raffoux E; Spertini O; Vey N; Marchand T; Récher C; Pigneux A; Girault S; Deconinck E; Gardin C; Tournilhac O; Lambert JF; Chevallier P; de Botton S; Lejeune J; Dombret H; Chevret S; Fenaux P
Haematologica; 2018 Dec; 103(12):2033-2039. PubMed ID: 30026341
[TBL] [Abstract][Full Text] [Related]
40. Progress in the treatment of acute promyelocytic leukemia: optimization and obstruction.
Li J; Zhu H; Hu J; Mi J; Chen S; Chen Z; Wang Z
Int J Hematol; 2014 Jul; 100(1):38-50. PubMed ID: 24938378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
